Figure 5. Lnc-EPIC1-MYC binding promotes colon cancer cell progression. The qPCR analyses of Lnc-EPIC1 enriched in the MYC protein in primary human colon cancer cells, pri-Can-1/-2/-3 (A). Western blotting analyses of the MYC protein retrieved by in-vitro-transcribed Lnc-EPIC1 in primary human colon cancer cells, pri-Can-1/-2/-3 (B). The primary human colon cancer cells, pri-Can-1, were transfected with scramble control siRNA (“scr”, 500 nM) or the applied Lnc-EPIC1 siRNA (si-Lnc-EPIC1-s1/si-Lnc-EPIC1-s2, 500 nM, for 48h), expression of listed proteins was shown (C). Expression of the listed proteins in pri-Can-1 cells with empty vector (“Vec”) or the Lnc-EPIC1-expression construct (“OE-Lnc-EPIC1-Line1/2”) was shown (D). Expression of MYC protein and Lnc-EPIC1 in stable pri-Can-1 cells with the CRISPR/Cas9 MYC-KO construct (“MYC-KO-1/MYC-KO-2”, two constructs with different sgRNAs) or the empty vector (“Cas-C”) was shown (E); Cells were further transfected with si-Lnc-EPIC1-s1 (500 nM, for 48h) or Lnc-EPIC1-expression construct (“OE-Lnc-EPIC1”, for 48h), and further cultured for the applied time periods, cell viability, proliferation and migration were tested by CCK-8 viability (F), nuclear EdU staining (G) and “Transwell” (H) assays, respectively, and results were quantified. Data presented as mean ± standard deviation (SD). Experiments in this figure were repeated five times.